Search results


Authorize the processing of personal data
Edit email address
Invalid email
Email Sent
Authorize the processing of personal data
You searched for:
Results: 57

Respiratory diseases

Chiesi Farmaceutici is fully committed to the care and improvement of the quality of life of people suffering from respiratory diseases including asthma and COPD (Chronic Obstructive Pulmonary Disease). Asthma and COPD are characterised by a reduction in the respiratory flow although they are...


Normally, delivery takes place between the 37th and the 42nd week of gestation. By that time, the foetus is fully formed and developed enough to be able to adapt to extra-uterine life. However, in some cases delivery may occur before the 37th week of gestation. In that case, the neonate is...


RENAL AND LIVER FAILURE - SOLID ORGANG TRANSPLANT (SOT) Organ failure happens when an organ loses its ability to perform its physiological functions, and this creates a potential threat to both the quality of life and the survival of the patient. The kidneys cover various physiological functions,...


Chiesi Farmaceutici S.p.A. is an international, privately-owned pharmaceutical company based in Parma, Italy. Chiesi dedicates itself to the research, development and sales of innovative medicines in the areas of respiratory, neonatology, transplant, rare diseases and others. The company was...

Research & development

Being able to offer innovative treatment options and thus improve the health and live of our patients is the engine that drives us. For this reason, research and development (R&D) is not only important to Chiesi as a company with a technological focus but it is also essential to us as a...


Chiesi Farmaceutici has a system of pharmacovigilance in order to assume liability for our medicinal products (whether marketed or under clinical development) and to take appropriate actions when necessary. We ensure that all information relevant to the benefit-risk ratio of our medicinal products...

Therapeutic Areas









Data privacy statement We are pleased about your visit to our website and your interest in our company and our products. We respect the privacy of all those who visit this website. Chiesi Pharmaceuticals GmbH is aware of the sensitivity of information and personal data in the area of...


This project was edited and produced by Dynamic Mind.





Ethics & compliance

The Code of Ethics and Conduct expresses the Group’s commitment to operate not only in accordance with the laws and regulations currently in force but also with certain principles and rules of conduct of an ethical nature. The application of the following principles is guaranteed...

Chiesi foundation

Founded in 2005, the Chiesi Foundation Onlus is a no-profit organisation which seeks to capitalise on Chiesi’s legacy of knowledge in order to promote health and alleviate the suffering of patients affected by chronic obstructive respiratory diseases, rare diseases and neonatal diseases. The...

Informații medicale


Search result


Working at Chiesi

  Job opportunities   Chiesi is continually looking for new talent for opportunities in all areas of the organization. Explore our global career portal and register to receive updates and current job openings.   Visit our global career portal here: Click here to...

Link Uri Utile



We consider ourselves a research-focused international Group, able to develop and commercialise innovative pharmaceutical solutions to improve the quality of human life. We wish to maintain a high quality entrepreneurial team characterised by self-confidence and a collaborative...








PRIVACY NOTICE   This privacy notice is provided by Chiesi Farmaceutici S.p.A., including its affiliates (together “Chiesi Group“ or “Chiesi”) in compliance with the applicable privacy regulations and is aimed at informing the reporting individuals on how we process...


Cookie Policy This policy provides information regarding the use of cookies and other similar technologies on the website referred to as the "Website"). This notice is provided to the user in compliance with European legislation on the processing of personal data...


PRIVACY NOTICE - Website Under Article 13 of Regulation (EU) 2016/679 on the protection of individuals regarding the processing of personal data (hereinafter "GDPR") This is a privacy notice provided by Chiesi Romania SRL "Chiesi"), in accordance with the provisions of European Regulation No....

Chiesi Group Announces Establishment of New Global Rare Diseases Division

Chiesi Group Announces Establishment of New Global Rare Diseases Division Specialized division focused on research and product development for rare and ultra-rare diseases highlights Chiesi’s commitment to building a brighter future for patients Chiesi Global Rare Diseases unit will...

Chiesi Group increases support measures and announces new funds for employees, patients and healthcare providers in response to COVID-19 pandemic

  The Group commits €3 million for donations to support the ongoing emergency Sustained efforts designed to ensure continuity of supply-chain and production despite increased restrictions in Italy and around the world Company also announces a €1 million investment in new...

Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH).

CAMBRIDGE, Mass. and Parma, Italy – September 16, 2020 – Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients and Chiesi Farmaceutici S.p.A., an international...

We ACT Day 2020: the third edition of Chiesi’s event for a sustainable future

This year, all of the Group’s affiliates, employees, communities and the company’s partners will be attending a virtual edition of the event to confirm Chiesi’s commitment towards people, the community and the environment.   Parma, 24th September 2020 – Chiesi...

Italy for Climate: Chiesi at the forefront for the future of Italy

Making the climate the pivot of the strategy for economic and employment recovery: this is the objective of Italy for Climate, the initiative promoted by the Fondazione per lo Sviluppo Sostenibile and a virtuous group of companies (Conou, Davines, e2i, ERG, illy, ING), including Chiesi Group, with...

Regeneration 20|3, the first global meeting to launch the program is in Parma on October 15 and 16.

The 20|30 temporal frontier is essential: we have no more than 10 years to give a concrete response to the problem of the climate change, while working on a new regenerative model that puts social equality, happiness and well-being of individuals at the center of the strategy, as well as economic...

Maria Paola Chiesi received by the President of the Italian Republic for the 2020 Bellisario Award ceremony

Chiesi Farmaceutici receives the award reserved to large Companies and recognises their outstanding contribution to gender equality and to enhancing the value of women in the workplace   Parma, October 15th, 2020 – Chiesi Farmaceutici, an international research-focussed pharmaceutical...

Chiesi USA, Inc. announces FDA approval of Bronchitol® (mannitol) inhalation powder

Bronchitol® indicated as add-on maintenance therapy to improve pulmonary function in adult patients with cystic fibrosis (CF)   CARY, NORTH CAROLINA, NOVEMBER 02, 2020 – Chiesi USA, Inc., the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused...

World Prematurity Day: Chiesi is at the forefront for preterm babies

November 17th it’s the World Prematurity Day (WPD). The WPD aims at raising awareness of the challenges of preterm birth globally, one of the largest cause of perinatal and neonatal mortality and morbidity in children (source: World Health Organization). Without an appropriate treatment,...

Chiesi launches “The Art of Caring”, a journey in search of the link between Parma, officinal treatments and pharmaceutics

Parma, November 17, 2020 – Chiesi Farmaceutici, an international research-focussed pharmaceutical group, announces the launch of the website A cultural and historical account consisting of three virtual itineraries which set out to discover some of the places...

Chiesi Group receives Diversity Leaders Award 2021

The Group achieves the 10th position (just one other Italian company is between the first 10), among the most inclusive companies in Europe and the 1st position in the Pharmaceutical and Biotechnology sector; In Italy, Chiesi ranks 2nd among the 35 companies qualifying for the...

Kaia Health and Chiesi Group Announce Strategic Partnership to Commercialise Kaia COPD Pulmonary Rehabilitation App in European Markets

Agreement marks a historic partnership for respiratory care in Europe     MUNICH and PARMA, November 30, 2020 - Kaia Health, a leading digital therapeutics company, and Chiesi Group, an international research-focused healthcare group, announced that they have entered into an exclusive...

“Infermieri, a viso aperto”, a photographic project bringing to light the faces and stories of those who help patients every day

At shots taken by photographer Settimio Benedusi visually tell the story of nursing professionals who are fundamental to our healthcare service. This virtual photographic exhibition was promoted and set up by the Chiesi Group under the patronage of the FNOPI, the...

Chiesi Headquarters: an innovative, sustainable and people-friendly “home”, the first building in its category to be certified “LEED Platinum” in Italy. A people-oriented project.

The Group’s head office in Parma: a new facility housing more than 540 employees. People, Innovation, Sustainability form the foundations on which the headquarters were built. Designed on the basis of a new vision of the workplace as a shared space, centred on respect for environment and...

Chiesi Group receives the European marketing authorisation for Trimbow® (beclometasone dipropionate, formoterol fumarate, glycopyrronium) an extrafine formulation fixed triple combination therapy for the treatment of asthma

Trimbow is the first extrafine formulation fixed triple combination therapy in a single inhaler to be approved for use in appropriate asthma patients.1,2 This follows the 2017 approval of this therapeutic option for the treatment of appropriate moderate to severe chronic obstructive pulmonary...

Chiesi Group: performance is up in 2020

The Chiesi Group currently employs 6,389 people worldwide, 2,119 of whom are in Italy and has a turnover of € 2 billion 229 million. Chiesi’s business comprises 30 affiliates, 7 research centres, 3 production sites and a commercial presence in a total of 90 countries. These results...

The Chiesi Group is on Twitter!

After the launch of Facebook in 2020 and the continuous growth of the Group’s activities on LinkedIn, Chiesi Group has decided to take a further step in the Social Media world to communicate more directly with its stakeholders.      On Twitter (as on Facebook and LinkedIn)...

Chiesi continues cultural transformation with new visual identity that mirrors patients’ language and experiences

New visual identity is the first public manifestation of Chiesi Group’s continued transformation as a B Corp certified business Patients’ experiences and perception of Chiesi at the heart of the new corporate identity   Parma (Italy), March 22, 2021 – Chiesi, the...

New record for the Chiesi Group, which is confirmed top Italian pharmaceutical company for number of patents filed

The Chiesi Group is the number one Italian pharmaceutical company and ranks fourth among Italian companies across all sectors for filing the highest number of patents. The details were published by the European Patent Office (EPO) when the 2020 official data relating to the number of patent...

D&I Policy: a further demonstration of Chiesi's commitment

At Chiesi Diversity & Inclusion (D&I) is part of our culture: as a Benefit company and a certified B Corp, we aim to further enhance an inclusive and open approach in our daily actions, ensuring the well-being of our people, openness to others, a sense of welcome and thus improving...

Chiesi Group receives European Marketing Authorisation for its triple combination therapy inhalation powder (beclometasone dipropionate, formoterol fumarate dihydrate and glycopyrronium) in extrafine fixed formulation delivered through NEXThaler, for the

Chronic obstructive pulmonary disease (COPD) patients for whom a dry powder inhaler device is preferred, can now benefit from an extrafine formulation fixed triple combination therapy containing an inhaled corticosteroid (ICS) / long-acting β2-agonist (LABA) / long-acting muscarinic...

Chiesi Group announces the passing of Honorary President Dr. Paolo Chiesi (1940-2024)

Parma, March 5th, 2024 - Chiesi Group announces the passing of Honorary President Dr. Paolo Chiesi, a fundamental pillar of the company who shaped its history alongside his brother Alberto.   Born in Parma in 1940 and graduating in Chemistry and Pharmacy, he led the Corporate Research and...

Beclometazonă + formoterol